Clinical trials for cancer treatment

  • July 9, 2015
Clinical trials for cancer treatment

New antibody treatment to be trialled on cancer patients in the UK.

We are very excited with our orphan oncology development strategy and proud of the experienced founding team we have assembled.

Chandler Robinson

An emerging biopharmaceutical company focused on developing orphan oncology compounds which was co-founded by Gates Cambridge Alumnus Chandler Robinson has joined forces with cancer research organisations in the UK to take an experimental antibody treatment into clinical trials with cancer patients.

Monopar Therapeutics LLC has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT) to take forward Monopar’s antibody treatment HuATN-658 into clinical trials in cancer patients with advanced solid tumours. HuATN-658 is an antibody that targets the cell surface protein uPAR, which is found in high levels in some of the most deadly cancers.

Under the agreement, Cancer Research UK’s Centre For Drug Development (CDD) will finance and complete preclinical development of HuATN-658 and conduct a Phase 1 clinical trial in cancer patients. While drug efficacy will be monitored, the trial’s main objective will be to evaluate the safety of the antibody. The trial will be managed and run by the CDD through the Experimental Cancer Medicine Centre (ECMC) network, a UK-wide initiative funded by Cancer Research UK and the UK’s four health departments. Upon completion of the clinical trial, Monopar has the right to acquire the clinical trial data. If Monopar declines the option, CRT may continue the development and commercialisation of HuATN-658 in exchange for a share to Monopar of any future revenue from the drug.  

Chandler D. Robinson [2009, pictured] is the co-founder and CEO of Monopar Therapeutics, which is the second company he started after completing his MBA at the University of Cambridge. He said: “This partnership, together with the completion of our first tranche of financing, are important steps in our establishment of Monopar as an emerging oncology therapeutics company. We are very excited with our orphan oncology development strategy and proud of the experienced founding team we have assembled. HuATN-658, our lead compound, was discovered by our Chief Scientific Officer, Dr Andrew Mazar, one of the world’s experts on the uPAR pathway. The development partnership with Cancer Research UK allows Monopar to leverage a strong platform for the clinical advancement of this compound as the group brings long established clinical, regulatory and manufacturing expertise and resources that would be difficult for an emerging company like Monopar to amass quickly.”

Christopher M. Starr, co-founder and former CEO of Raptor Pharmaceuticals and co-founder and Executive Chairman of Monopar Therapeutics, said: “A partnership with Cancer Research UK is a strong first step in Monopar’s pipeline development and validates the potential for HuATN-658 as an oncology therapeutic. Cancer Research UK is recognised globally for having the quality, capability and track record of successfully advancing clinical stage drug development programs. This is an important development milestone for HuATN-658, and we are looking forward to building an exciting pipeline of orphan oncology drug candidates at Monopar.”

Dr Nigel Blackburn, Cancer Research UK’s Director of Drug Development, said: “We’re excited to be working with Monopar Therapeutics to take this promising new treatment a step further on its journey towards the clinic. The collaboration forms part of our Clinical Development Partnerships scheme, which aims to help release promising treatments from drug company pipelines and bring them into early phase trials sooner. Thanks to this, six new treatments are now in clinical trials that may otherwise never have progressed beyond the lab.”

*Picture credit: "Adenocarcinoma highly differentiated (rectum) H&E magn 400x". Licensed under Public Domain via Wikimedia Commons.

Latest News

The process of history-making

Olin Moctezuma-Burns [2020] is keen not to repeat the patterns of some past researchers and to give back to the communities she studies. For that reason she recently co-organised an international gathering of Imagining Futures projects on archiving indigenous and traditional knowledges in Sotuta, Yucatan. The meeting brought together people from Colombia, Peru, Kenya, Tanzania, […]

How might extreme heat contribute to human migration?

Rising temperatures due to climate change are likely influencing human migration patterns, according to a new study co-authored by Gates Cambridge Scholar Dr Kim van Daalen [2018]. The study, led by Rita Issa of University College London, is published today in the open-access journal PLOS Climate. It looks at the role of heat in human […]

Scholar scoops prestigious science innovation fellowship

Freja Ekman has been named one of the 2023 class of Hertz Fellows as the prestigious fellowship celebrates its 60th year. The 15 fellowships in applied science, engineering and mathematics are awarded by Fannie and John Hertz Foundation, a non-profit organisation for innovators in science and technology. Winners will have their graduate studies funded for […]

Scholar hosts first UN communications technology access meeting in India

Gates Cambridge Scholar Pradipta Biswas has hosted a UN meeting on improving access to communications technology – the first ever held in India. The meeting of ITU-T Study Group 9 (SG-9) on “Broadband Cable and Television/Audiovisual content transmission and integrated broadband cable networks”  was held in May at the Indian Institute of Science in Bengaluru […]